HANS-PETER GERBER, Ph.D

Chief Scientific Officer

Hans-Peter Gerber, Ph.D., has served as Chief Scientific Officer of Sutro since September 2023, bringing more than three decades experience in advancing transformative biologics in oncology, with deep expertise in antibody-drug conjugates (ADCs), redirected T-cell engagers, and cell-based immunotherapies.

Prior to Sutro, Hans-Peter co-founded Codeable Therapeutics in 2022 to advance next-generation ADCs engineered to elicit immunogenic cell death and deepen antitumor immune responses. He also served as Chief Scientific Officer and SVP at 3T Biosciences, where he completed an oversubscribed Series A while serving as interim Chief Executive Officer. Previously, Hans-Peter built the R&D organization at Maverick Therapeutics, leading to its acquisition by Takeda in 2021, and served as an independent director at NBE Therapeutics, acquired by Boehringer Ingelheim in 2021.

Earlier in his career, he held scientific leadership roles at Genentech, Seattle Genetics, and Pfizer, overseeing multiple oncology programs from discovery through IND submission. His work contributed to more than 10 IND filings, including seven ADCs, and to three BLAs, including Avastin®, Mylotarg®, and Besponsa®.

An internationally recognized leader in oncology R&D, Hans-Peter has authored over 100 peer-reviewed publications, holds over 100 patents, and has contributed to the development of six of the 15 FDA-approved ADCs. He also serves as Chairman of the Board at T-CURX in Germany and as a board member at Athebio in Switzerland. Hans-Peter received his M.S. in Biochemistry and Ph.D. in Molecular Biology from the University of Zurich, Switzerland.